UNSPSC 51351608: Estriol

This classification denotes a steroidal estrogen with the molecular formula C18H24O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FB33469R8E, chemically known as 3,16beta,17beta-trihydroxy-1,3,5(10)-estratriene but generally known as estriol, which bears US NIH Compound Identifier 3269. European Medicines Agency schedules Estriol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01971MIG. World Health Organization schedules estriol in its Anatomical Therapeutic Chemical (ATC) Classification.

UNSPSC 51351608 Estriol is a Commodity code for a specific pharmaceutical active ingredient typically supplied as part of broader multi-source generic and over-the-counter pharmaceutical procurement programs. State and local governments buy this product as part of larger pharmaceutical sourcing contracts that consolidate multiple active pharmaceutical ingredients and OTC items for distribution across state health agencies, corrections facilities, public health departments, and other government healthcare operations. Solicitations under this code generally require vendors to supply products through established pharmaceutical wholesalers, maintain cGMP and Drug Supply Chain Security Act compliance, hold comprehensive insurance coverage, and meet strict product-availability and shelf-life standards. Issuing bodies include state cooperative purchasing alliances administering multi-state pharmaceutical programs, individual state health and human services departments, and participating local government entities within cooperative frameworks.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with a proposal due date of March 26, 2026. The solicitation (S1070000015802) covers products distributed across Minnesota, Oregon, and other participating state and local government facilities; vendors must supply through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) and maintain contractual relationships with at least two of them. The contract term is two years for new vendors with optional MMCAP extensions, or alignment with existing expiration dates through June 30, 2028 for incumbent vendors. Evaluation emphasizes price competitiveness at 75 percent weight, with the remaining 25 percent distributed among fixed pricing, administrative compliance, EDI capability, and acceptance of a 3 percent administrative fee. All products must be available in the marketplace by May 15, 2026, and awarded vendors will be provided to wholesalers with agreements effective July 1, 2026.